Solid Biosciences Inc’s recent filing unveils that its Director Kahn Clare acquired Company’s shares for reported $8442.0 on Jun 07 ’24. In the deal valued at $7.67 per share,1,100 shares were bought. As a result of this transaction, Kahn Clare now holds 1,100 shares worth roughly $6655.0.
Then, Ganot Ilan sold 462 shares, generating $4,772 in total proceeds. Upon selling the shares at $10.33, the Director now owns 9,507 shares.
Before that, Ganot Ilan sold 139 shares. Solid Biosciences Inc shares valued at $1,111 were divested by the Director at a price of $7.99 per share. As a result of the transaction, Ganot Ilan now holds 8,416 shares, worth roughly $50916.799999999996.
JP Morgan upgraded its Solid Biosciences Inc [SLDB] rating to an Overweight from a a Neutral in a research note published on July 15, 2024; the price target was increased to $15 from $10. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in late June from “a Market perform” to “an Outperform”. William Blair started covering the stock on March 28, 2024. It rated SLDB as “an Outperform”.
Price Performance Review of SLDB
On Friday, Solid Biosciences Inc [NASDAQ:SLDB] saw its stock unchanged to $6.05. Over the last five days, the stock has lost -8.05%. Solid Biosciences Inc shares have fallen nearly -1.47% since the year began. Nevertheless, the stocks have risen 163.04% over the past one year. While a 52-week high of $15.05 was reached on 03/28/24, a 52-week low of $1.81 was recorded on 01/04/24. SMA at 50 days reached $7.87, while 200 days put it at $8.66.
Levels Of Support And Resistance For SLDB Stock
The 24-hour chart illustrates a support level at 5.83, which if violated will result in even more drops to 5.61. On the upside, there is a resistance level at 6.20. A further resistance level may holdings at 6.35. The Relative Strength Index (RSI) on the 14-day chart is 32.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.51, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.88%. Stochastics %K at 16.64% indicates the stock is a buying.
How much short interest is there in Solid Biosciences Inc?
A steep rise in short interest was recorded in Solid Biosciences Inc stocks on 2024-09-30, growing by 41486.0 shares to a total of 1.73 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 1.69 million shares. There was a rise of 2.4%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 15, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $16 price target.
